New obesity drug enters final testing phase against leading treatment
NCT ID NCT07285902
Summary
This study aims to see if a new weekly injection called HRS9531 works as well or better than the established drug semaglutide for weight loss in adults with obesity. About 572 participants will receive one of the two injections for 52 weeks while researchers track changes in body weight, health measures, and side effects. The goal is to provide another effective treatment option for managing obesity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiness PLA General Hospital
Beijing, Beijing Municipality, 100853, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.